September 18, 2012 Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
August 8, 2012 Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
May 14, 2012 Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
March 14, 2012 Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
